Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04938193
Other study ID # CHUBX 2019/24
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date February 2, 2022
Est. completion date February 2025

Study information

Verified date January 2023
Source University Hospital, Bordeaux
Contact Frédéric-Antoine DAUCHY, MD
Phone 05 56 79 55 36
Email frederic.dauchy@chu-bordeaux.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Diagnosis of chronic prosthetic joint infection (PJI) can be difficult. 68Ga-citrate Positron Emission Tomography/Computed Tomography (PET/CT) has been recently developed and has many advantages such as high resolution and low radiation exposure. To date, 68Ga-citrate PET/CT has not been specifically assessed in prosthetic joint infection. In this prospective study, patients referred for a suspected PJI will benefit from both a 68Ga-citrate PET/CT and a 99mTc-HMPAO-labelled leukocyte SPECT/CT. The primary outcome is the assessment of the 68Ga-citrate PET/CT accuracy for the diagnosis of chronic prosthetic hip or knee infection.


Description:

Prosthetic joint infection (PJI) is a serious and rare complication of orthopedic surgery. Diagnosis is based on precise criteria (MSIS criteria Musculoskeletal Infection Society). However, diagnosis can be difficult, in particular when the infection is present for more than one month. One of the usual exams is bone scintigraphy and 99mTc-HMPAO-labelled leukocyte scintigraphy. This imaging allows an accurate assessment but it has some limitations since it requires ex vivo isolation and marking of patient's leukocytes and repeated acquisition for 24 hours. 68Gallium-citrate positron emission tomography/computed tomography (68Ga-citrate PET/CT) has been recently developed. 68Ga-citrate PET/CT is innovative compared to [18F]fluorodeoxyglucose PET/CT (18F-FDG PET/CT) and has many advantages: high resolution, realization in only two hours, short radioactive period and no handling of patient's leukocytes. Furthermore, preliminary data indicate that 68Ga-citrate is picked up by immune cells, which makes this exam inflammation-selective. To date, 68Ga-citrate PET/CT has not been specifically assessed in PJI, it is the objective of the present study: Prospective study using 68Ga- citrate PET/CT and a 99mTc-HMPAO-labelled leukocyte SPECT/CT. Patients referred for a suspected PJI and with a positive bone scintigraphy will be prospectively enrolled. After information and signature of informed consent, patients will benefit from a 68Ga citrate PET/CT, in addition to leukocyte scintigraphy in a two-week period. Both images will be anonymized and interpreted by two independent nuclear physicians. Final PJI diagnosis is based on reference criteria (MSIS) to ensure diagnosis during the standardized medical follow-up. Patients will be followed until 12 months after the leukocyte scintigraphy.


Recruitment information / eligibility

Status Recruiting
Enrollment 35
Est. completion date February 2025
Est. primary completion date February 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient aged over 18 years old - Patient referred for the first time to the South-Western France referral center for complex bone and joint infections (Crioac GSO, infectious diseases and orthopedic surgery units) for suspicion of prosthetic hip or knee infection. - Suspicion of prosthetic joint infection evolving for more than one month. - Patient for who routine diagnosis includes both bone scintigraphy and leukocytes scintigraphy. - Patient with positive bone scintigraphy. - Being affiliated to a health insurance system - Having signed an informed consent form (later than the day of inclusion and before any examination required by the research) Exclusion Criteria: - Patient with active cancer. - Patient with negative bone scintigraphy. - Patient who cannot stop antibiotics 14 days before exams. - Pregnant or breastfeeding women. - Women of childbearing age but not using effective means of contraception. - Patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent). - Subject in relative exclusion period from another study protocol. - Known contraindications to PET exam with radiopharmaceutical injection (hypersensitivity to radiopharmaceutical and/or to excipients).

Study Design


Intervention

Diagnostic Test:
68Ga-citrate PET/CT
PET/CT Imaging with 68Ga-citrate PET/CT injection

Locations

Country Name City State
France CHU de Bordeaux - service de maladies infectieuses Bordeaux

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diagnostic accuracy of 68Ga citrate PET / CT scan CT for chronic prosthetic hip or knee infection Sensibility, specificity, positive and negative predictive value. Index test : 68Ga citrate PET / CT scan CT at inclusion. Reference test : Musculoskeletal Infection Society (MSIS) criteria assessed up to 12 months after inclusion. After 12 months, participants will be considered free of chronic prosthetic hip or knee infection. Up to 12 months after baseline (Day 0)
Secondary Diagnostic accuracy of quantitative 68Ga citrate PET / CT scan for chronic prosthetic hip or knee infection Area under ROC curve (AUROC) for SUVmax ROI and SUVmax ROI/SVmax liver region ratio measured at inclusion.
Reference test : Musculoskeletal Infection Society (MSIS) criteria assessed up to 12 months after inclusion.
Up to 12 months after baseline (Day 0)
Secondary Inter-observer reproducibility of 68Ga-citrate PET/CT interpretation Intraclass correlation coefficient and/or Cohen's Kappa. Up to 12 months after baseline (Day 0)
Secondary Diagnostic accuracy of leukocyte scintigraphy for chronic prosthetic hip or knee infection Sensibility, specificity, positive and negative predictive values. Index test : leukocytes scintigraphy at inclusion. Reference test : Musculoskeletal Infection Society (MSIS) criteria assessed up to 12 months after inclusion. Up to 12 months after baseline (Day 0)
Secondary Diagnosis accuracy of 68Ga-citrate PET/CT and leukocytes scintigraphy for chronic prosthetic hip or knee infection in the following sub-groups: prosthetic knee or hip infection. Sensibility, specificity, positive and negative predictive values, in each subgroup.
Index test : 68Ga citrate PET / CT scan CT at inclusion. Reference test : Musculoskeletal Infection Society (MSIS) criteria assessed up to 12 months after inclusion. After 12 months, participants will be considered free of chronic prosthetic hip or knee infection.
Up to 12 months after baseline (Day 0)
Secondary Comparison of diagnostic accuracy of 68Ga-PET/CT and leukocytes scintigraphy for chronic prosthetic hip or knee infection Sensibility, specificity, positive and negative predictive values. Reference test : Musculoskeletal Infection Society (MSIS) criteria assessed up to 12 months after inclusion.
Index test : 68Ga citrate PET / CT scan CT at inclusion and leukocytes scintigraphy at inclusion.
Up to 12 months after baseline (Day 0)
See also
  Status Clinical Trial Phase
Completed NCT04067843 - Effect of Photodynamic Treatment on Skin Microbiome. Single Center Study N/A
Enrolling by invitation NCT05247281 - NGS vs Culture Outcomes for Treatment of PJI N/A
Withdrawn NCT05269121 - Bacteriophage Therapy in First Time Chronic Prosthetic Joint Infections Phase 1/Phase 2
Recruiting NCT02801253 - Cohort of Prosthetic Joint Infections
Completed NCT03694925 - Diagnostic Utility of a Novel Point-of-Care Test of Calprotectin for Revision Total Knee Arthroplasty
Completed NCT03721328 - Safety and Efficacy in Patients Treated for Hip or Knee PJI With Vancomycin and Tobramycin Joint Irrigation Phase 2
Withdrawn NCT04787250 - Bacteriophage Therapy in Patients With Prosthetic Joint Infections Phase 1/Phase 2
Recruiting NCT03307109 - Quality of Life in Patients Having a Prosthetic Joint Infection
Recruiting NCT04661345 - Identification of Molecular Marker of Coagulase-negative Staphylococci for the Diagnosis of Prosthetic Joint Infections
Recruiting NCT02805803 - Quality of Life Assessment in Patients Undergoing Prolonged Suppressive Antibiotherapy for Prosthetic Joint Infection. N/A
Completed NCT02413034 - The Influence of Antibiotic Prophylaxis on Intraoperative Prosthetic Joint Infection Cultures N/A
Recruiting NCT03784807 - New Strategies for Biofilm Related Infections
Completed NCT04662632 - Abbreviated Protocol for Two-Stage Exchange Phase 2
Not yet recruiting NCT04390607 - Leukocyte Esterase Sensor Test
Recruiting NCT04650607 - Phage Safety Cohort Study
Active, not recruiting NCT04946500 - Clindamycin in Prosthetic Joint Infections Caused by Staphylococcus (CISTA)
Recruiting NCT04762706 - Measuring Distress in Prosthetic Joint Infection Using a Standardized Metric: CRUTCH Pathway Pilot. N/A
Withdrawn NCT05269134 - Bacteriophage Therapy in Patients With Prosthetic Joint Infections (PJI) Phase 2
Not yet recruiting NCT05239312 - Antibiogram and Biofilm Formation of Bacteria Causing Prosthetic Joint Infections Isolated From Assiut University Hospital
Completed NCT04294862 - Tissue Distribution, Pharmacokinetics, Safety, and Tolerability After a Single Dose of TNP-2092 in Participants Undergoing Primary Total Hip or Knee Arthroplasty Phase 1